Oncolytics Biotech Inc (ONCY)
1.04
0.00 (0.00%)
USD |
NASDAQ |
Apr 23, 16:00
1.05
+0.01
(+0.96%)
After-Hours: 20:00
Oncolytics Biotech Enterprise Value: 52.12M for April 23, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 23, 2024 | 52.12M |
| April 22, 2024 | 52.12M |
| April 19, 2024 | 53.63M |
| April 18, 2024 | 51.37M |
| April 17, 2024 | 52.12M |
| April 16, 2024 | 55.14M |
| April 15, 2024 | 53.63M |
| April 12, 2024 | 59.66M |
| April 11, 2024 | 60.42M |
| April 10, 2024 | 58.91M |
| April 09, 2024 | 61.17M |
| April 08, 2024 | 61.17M |
| April 05, 2024 | 60.42M |
| April 04, 2024 | 60.42M |
| April 03, 2024 | 56.64M |
| April 02, 2024 | 54.38M |
| April 01, 2024 | 53.63M |
| March 28, 2024 | 53.63M |
| March 27, 2024 | 51.37M |
| March 26, 2024 | 49.86M |
| March 25, 2024 | 51.37M |
| March 22, 2024 | 49.10M |
| March 21, 2024 | 51.37M |
| March 20, 2024 | 49.86M |
| March 19, 2024 | 51.37M |
| Date | Value |
|---|---|
| March 18, 2024 | 52.12M |
| March 15, 2024 | 48.27M |
| March 14, 2024 | 50.61M |
| March 13, 2024 | 52.12M |
| March 12, 2024 | 53.63M |
| March 11, 2024 | 53.63M |
| March 08, 2024 | 52.87M |
| March 07, 2024 | 52.12M |
| March 06, 2024 | 51.08M |
| March 05, 2024 | 50.34M |
| March 04, 2024 | 42.15M |
| March 01, 2024 | 57.04M |
| February 29, 2024 | 58.53M |
| February 28, 2024 | 49.60M |
| February 27, 2024 | 51.08M |
| February 26, 2024 | 47.36M |
| February 23, 2024 | 47.13M |
| February 22, 2024 | 50.71M |
| February 21, 2024 | 49.60M |
| February 20, 2024 | 57.78M |
| February 16, 2024 | 60.01M |
| February 15, 2024 | 60.01M |
| February 14, 2024 | 59.27M |
| February 13, 2024 | 51.83M |
| February 12, 2024 | 56.29M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
1.164M
Minimum
Oct 02 2019
205.30M
Maximum
Apr 08 2021
69.01M
Average
63.55M
Median
Nov 17 2021
Enterprise Value Benchmarks
| Acasti Pharma Inc | 1.956M |
| Aurinia Pharmaceuticals Inc | 384.89M |
| Edesa Biotech Inc | 9.894M |
| Lexaria Bioscience Corp | 23.70M |
| Xenon Pharmaceuticals Inc | 2.461B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.901M |
| Total Expenses (Quarterly) | 6.500M |
| EPS Diluted (Quarterly) | -0.0367 |
| Earnings Yield | -29.29% |